Modern Physiotherapeutic Methods in Humans
Not Applicable
- Conditions
- Health Condition 1: null- Supporting the treatment of injuries in sports and rehabilitation of patientsHealth Condition 2: T07- Unspecified multiple injuries
- Registration Number
- CTRI/2018/01/011344
- Lead Sponsor
- udwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Torun Poland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Applicable
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Individuals diagnosed by a physician with recommendation for appropriate therapy.
Exclusion Criteria
neoplastic diseases, myocardial infarction, surgery performed in the last six months, infectious (bacterial, viral) diseases, lack of contact with the patient - advanced dementia changes, no voluntary consent to the examination, bad feeling of the patient on the day of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Physical examination: <br/ ><br>a. physical examination (assessment of muscular strength and tension, joint mobility, assessment of maximum pain points), <br/ ><br>b. ultrasonography of diseased tissue, <br/ ><br>c. examination of surface muscle tension - electromyography, <br/ ><br>d. assessment of limb load and balance using stabilometric or dynamic platform.Timepoint: Two study timepoints: before and after the 10-day therapy.
- Secondary Outcome Measures
Name Time Method Examination of patientsâ?? peripheral blood: <br/ ><br>- erythrocytic activity of superoxide dismutase, catalase and glutathione peroxidase, as well as the concentration of thiobarbituric acid reactive substances (TBARS) and conjugated dienes (CD) <br/ ><br>- plasma concentration of TBARS, CD, malondialdehyde and vitamins A and E. <br/ ><br>- serum activity of arylsulfatase, acid phosphatase, cathepsin D, alpha1-antitrypsin, interleukin-1β, interleukin-6, tumor necrosis factor alpha and tumor growth factor beta1. <br/ ><br> <br/ ><br>Timepoint: Before the 10-day therapy, during the therapy (7 days from start of the study) and 4 days after the therapy completion (14 days from start of the study)